Management of 'no-reflow' complicating reperfusion therapy

Acute Cardiac Care

Volumn 10, Issue 1, 2008, Pages 5-14

  Lee, Kaeng W ^a   Norell, Michael S ^a  

^a ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Adenosine; Distal embolic protection devices; Intracoronary verapamil; Myocardial perfusion; No reflow

Indexed keywords

ABCIXIMAB; ADENOSINE; ADRENALIN; DILTIAZEM; GLYCERYL TRINITRATE; HEPARIN; NICARDIPINE; NICORANDIL; NITROPRUSSIDE SODIUM; PAPAVERINE; VERAPAMIL;

ANGIOGRAPHY; ARTIFICIAL EMBOLISM; BLOOD VESSEL OCCLUSION; CATHETER; CLINICAL TRIAL; CORONARY STENT; DEVICE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EMBOLISM; EPICARDIUM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEMODYNAMICS; HUMAN; LOW DRUG DOSE; MICROANGIOPATHY; NO REFLOW PHENOMENON; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; REPERFUSION; REVIEW; SAPHENOUS VEIN GRAFT; SINGLE DRUG DOSE; THROMBECTOMY; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

ACUTE CORONARY SYNDROME; ADENOSINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BALLOON OCCLUSION; CORONARY ANGIOGRAPHY; DIAGNOSIS, DIFFERENTIAL; FILTRATION; HUMANS; MYOCARDIAL REPERFUSION; NITROPRUSSIDE; NO-REFLOW PHENOMENON; PROSTHESES AND IMPLANTS; VASODILATOR AGENTS; VERAPAMIL;

EID: 45849094718     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940701744318     Document Type: Review

References (47)

1. Kloner RA. Foreword - No-reflow: Basic science to a clinical phenomenon. Basic Res Cardiol. 2006;101:357-8.
2. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001;22:729-39.
3. Takahashi T, Anzai T, Yoshikawa T, Asakura Y, Ishikawa S, Mitamura H, et al. Absence of preinfarction angina is associated with a risk of no-reflow phenomenon after primary coronary angioplasty for a first anterior wall acute myocardial infarction. Int J Cardiol. 2000;75:253-60.
4. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 1995;75:778-82.
5. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation. 1994;89:2514-8.
6. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145:42-6.
7. Tsubokawa A, Ueda K, Sakamoto H, Iwase T, Tamaki S. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ J. 2002;66:1119-23.
8. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart. 2003;89:731-7.
9. Lee CH, Wong HB, Tan HC, Zhang JJ, Teo SG, Ong HY, et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry. J Interv Cardiol. 2005;18:261-6.
10. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification. Heart. 2004;90:123-5.
11. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656-62.
12. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125-30.
13. Klein LW, Kern MJ, Berger P, Sanborn T, Block P, Babb J, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2003;60:194-201.
14. Chen JP. Dual lumen catheters: more than just aspiration. J Invasive Cardiol. 2006;18:346.
15. Wilson RF, Laxson DD, Lesser JR, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet. 1989;1:807-11.
16. Kern MJ. Adenosine boluses: a cure for 'no-reflow'? Cathet Cardiovasc Diagn. 1998;45:366-7.
17. Granger CB. Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol. 1997;79:44-8.
18. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no reflow' phenomenon. Catheter Cardiovasc Interv. 2000;51:27-31.
19. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005;96:1410-5.
20. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775-80.
21. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27:2400-5.
22. Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51:394-9.
23. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14:299-302.
24. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444-51.
25. Taniyama Y, Ito H, Morishita R, Ogihara T. Potential of microvascular reperfusion with adjunctive pharmacological intervention: its impact on myocardial perfusion and functional outcomes in patients with acute myocardial infarction. Drugs. 2001;61:437-41.
26. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol. 2001;37:1335-43.
27. Barcin C, Denktas AE, Lennon RJ, Hammes L, Higano ST, Holmes DR Jr, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv. 2004;61:484-91.
28. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358-61.
29. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152:887-914.
30. Wohrle J, Grebe OC, Nusser T, Al Khayer E, Schaible S, Kochs M, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840-3.
31. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002;106:3063-7.
32. Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, et al. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J. 2006;27:920-8.
33. Skelding KA, Goldstein JA, Mehta L, Pica MC, O'Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv. 2002;57:305-9.
34. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-90.
35. Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, et al. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J. 2006;151:915-7.
36. Silva-Orrego P, Colombo P, Bigi R, Gregori D, Delgado A, Salvade P, et al. Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol. 2006;48:1552-9.
37. Cura FA, Escudero AG, Berrocal D, Mendiz O, Trivi MS, Fernandez J, et al. Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR). Am J Cardiol. 2007;99:357-63.
38. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063-72.
39. Limbruno U, De Caterina R. EMERALD, AIMI, and PROMISE: Is there still a potential for embolic protection in primary PCI? Eur Heart J. 2006;27:1139-45.
40. Antoniucci D. Rheolytic Thrombectomy in acute myocardial infarction: The Florence experience and objectives of the multicenter randomized jetstent trial. J Invasive Cardiol. 2006;18:32C-4C.
41. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996;39:113-8.
42. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278-84.
43. Hendler A, Aronovich A, Kaluski E, Zyssman I, Gurevich Y, Blatt A. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow. J Invasive Cardiol. 2006;18:32-6.
44. Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J. 2006;70:1099-104.
45. Petronio AS, De Carlo M, Ciabatti N, Amoroso G, Limbruno U, Palagi C. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005;150:1015.
46. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2004;63:171-6.
47. Huang RI, Patel P, Walinsky P, Fischman DL, Ogilby JD, Awar M, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:671-6.